Equillium, Inc. is a biotechnology company specializing in the development and sale of products to treat autoimmune and inflammatory disorders. Their main product, itolizumab, is a monoclonal antibody that targets a novel immune checkpoint receptor CD6 in Phase III clinical trials for acute graft-versus-host disease treatment. The company also develops EQ101 and EQ102 to treat cutaneous T cell lymphoma, alopecia areata, and various gastrointestinal diseases.